Pharmacological inhibition of mTOR by rapamycin would have a wide range of clinical effects, so it can benefit patients with tumors while the use of rapamycin monotherapy in a broad spectrum of metabolic diseases is limited due to its modest efficacy. The gene discussed is MTOR; the disease is metabolic disease.